E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Add to balance / Manage account  User:  Log out
Prospect News home > News index > List of issuers S > Headlines for SuperGen, Inc. > News item
Published on 1/27/2009 in the Prospect News Special Situations Daily.

Biotechnology Value Fund cuts stake to 10.72% in SuperGen

By E. Janene Geiss

Philadelphia, Jan. 27 - Biotechnology Value Fund, LP decreased its investment to 10.72% in SuperGen, Inc. as of Dec. 31, according to an SC 13G/A filing with the Securities and Exchange Commission.

That represents a passive stake of 6,171,399 shares.

Those holdings are down from the passive stake of 11%, or 6,299,900 shares, that the investor reported on March 11, 2008, according to an SC 13G/A filing.

SuperGen is Dublin, Calif., pharmaceutical company.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.